Johnson & Johnson Announces 2010 Results Bortezomi First Breaks 1 Billion

Business News Agency January 27th Recently, Johnson & Johnson announced its 2010 results, with annual sales of 61.587 billion U.S. dollars, a year-on-year decrease of 0.5% and net profit of 13.3 billion U.S. dollars, an increase of 8.7% year-on-year. Drug sales were 22.4 billion yuan, a year-on-year decrease of 0.6%. The division by region was the largest in the U.S. market, down 4% year-on-year.

In terms of high-quality products, REMICADE (infliximab, trade name: gram) maintained steady growth with sales of US$4.6 billion in 2010, a year-on-year increase of 7.1%. The anti-tumor drug VELCADE (bortezomib, trade name: Van Gogh), for the first time in 2010 sales exceeded 1 billion US dollars mark, an increase of 15.8%. Among the new products, the most significant growth was in the anti-AIDS drug PREZISTA (darunavir, trade name: senior), which recorded a significant increase of 44.8% year-on-year and sales of US$800 million. The product was approved by the FDA in 2006 and listed in 2008. Re-approved 4 kinds of specifications listed. While other high-end products showed negative growth at different levels, among them, TOPAMAX (topiramate, trade name: Topaz) was affected by the expiration of the patent, which fell by 53.3% year-on-year.

In China, J&J’s competitive products are sold by Xi’an Janssen’s agents. In addition to the above-mentioned products, they are also beneficial to Keshen (trade name: Risofon) and fentanyl transdermal patch (trade name: DuoRui Ji). According to the statistics of the competition pattern of the clinical drug use of risperidone (trade name: Tiida), Johnson's competitive products accounted for nearly 40% of the market share of Xi'an Janssen.